QualTex Laboratories, a subsidiary of San Antonio-based nonprofit BioBridge Global, has begun testing blood and plasma donations on its second automated track system, expanding its capabilities in its San Antonio laboratory.

Profiling MMV portfolio compound activity against the complete P. berghei liver stage.Scope includes compound screenings and portfolio compound testing where data will be delivered within 2 weeks of the end of the test run.

This is a multicenter, phase 3, double-blind, randomized, placebo-controlled study. Patients who qualify for study inclusion will be randomized in a 1:1:1 manner to receive MGL-3196 100 mg, MGL-3196 80 mg, or matching placebo given orally once daily in the morning for up to 54 months. If any patient has a Composite clinical outcome event on the Week 52 liver biopsy or any clinical composite event after Week 52 and prior to month 54 they will discontinue from the main study and will be allowed to participate in an open-label study on active treatment with MGL-3196.

The primary objective of this study is to demonstrate the long-term safety and efficacy of ozanimod for the treatment of subjects with moderate to severely active Crohn's disease (CD).

Whereas, the Federal Laboratory and the Collaborating Party are entering into this Agreement for the mutual benefit of each Party.  This joint research project will benefit the Collaborating Party by accomplishing its mission to promote and support the advancement of military medicine and specifically military medical research.  The project will benefit the Federal Laboratory by providing valuable research experience for the medical residents of the teaching program involved.  In addition, patients at SAMMC with moderately to severely active Crohn's Disea

The major goal of this project is to use a new tool like CRISPR/Cas13d to cleave HIV RNA. An HIV RNA-targeting strategy that efficiently and simultaneously targets multiple conserved sites , will result in the eradication of HIV from the cells.

Many genes including those associated with viral infections undergo differential splicing in different human populations. The aim of this study is to identify and quantify these differences and investigate their role in differential antiviral immunity among human populations.

In 2017, an estimated 10 million people developed TB disease, demonstrating an urgent need for new approaches to therapy, including host-directed therapy (HDT), to halt infection and progression of active TB. To this end, the overall goal of our ongoing research program is to identify intracellular ?master regulators? of inflammation and metabolic intermediates that dictate human macrophage responses to Mycobacterium tuberculosis infection as a strategy to identify potential host cell targets for HDT.

The objective of this research proposal is to further prove the concept that peptide mimics of the protective epitopes of PI-LPS are sufficient to confer protective immunity against C. burnetii aerosol infection. As a subcontract, Dr. Zhang will provide expert advice and guidance in experimental designing, data interpretation and problems solving as needed by ZenVax LLC in support of this project. In order to facilitate the ZenVax LLC’s effort to develop a mimotope vaccine against Q fever, Dr.

Coxiella burnetii is an obligate intracellular Gram-negative bacterium that causes acute and chronic Q fever in humans. There is an urgent need to create a safe and effective vaccine for prevention of human Q fever. However, the mechanisms of vaccine-induced immunity against C. burnetii natural infection remain unclear. The long-term goal of this project is to develop a safe and effective vaccine against Q fever.